GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the Company’s management will be attending and presenting at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place December 3-4, 2024, in Boca Raton, Florida.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Man Group PLC : Form 8.3 – Aviva plc - December 4, 2024
- Finantsinspektsioon confirmed the capital requirements and guidance of Coop Pank AS at the current level - December 4, 2024
- The Coretec Group Secures Controlling Stake of Multi-National Energy Company With Over US$70M in Annual Revenues; Strengthens Board and Introduces Global Expansion Plans - December 4, 2024
